The PROSTATE-IQ trial uses the ArteraAI Prostate Test to personalize treatment for prostate cancer recurrence post-prostatectomy, potentially reducing hormone therapy use. The trial stratifies ...

PRO-XTEN dual masking aims to keep the engager inactive in circulation, activate within tumor protease-rich microenvironments ...

Please provide your email address to receive an email when new articles are posted on . Many men with metastatic hormone-sensitive prostate cancer have not received recommended first-line treatment.

Preclinical results were recently presented from studies conducted by Fulcrum Therapeutics Inc. evaluating FTX-6274, a novel, orally bioavailable embryonic ectoderm development (EED) inhibitor that ...

New findings from VCU Massey Comprehensive Cancer Center and the VCU Institute of Molecular Medicine (VIMM), published in ...